Create issue ticket

4,067 Possible Causes for Activity, Peroxisome, Proliferator Activated, Receptor

  • Troglitazone

    Abstract Agonist ligands for the nuclear receptor peroxisome proliferator-activated receptor-gamma have been shown to induce terminal differentiation of normal preadipocytes[] Abstract The role of the peroxisome proliferator-activated receptor-γ (PPARγ) in cell differentiation, cell cycle arrest and apoptosis has attracted increasing attention.[] […] in T-lymphocyte activation.[] In the present study, we showed that co-treatment with troglitazone (TGZ), a synthetic ligand of peroxisome proliferator-activated receptor γ (PPARγ), and TRAIL synergistically[]

  • Telmisartan

    Peroxisome proliferator-activated receptor δ (PPARδ), a versatile regulator of metabolic homeostasis, may be a potential therapeutic target.[] Our results indicate that telmisartan can be considered as a novel AMPK activator, suppressing microglia activation by promoting M2 polarization.[] In humans, mutations in the peroxisome proliferator-activated receptor-gamma (PPARgamma) have been reported to cause the full-blown metabolic syndrome, and drugs that activate[] Peroxisome proliferator-activated receptor-δ (PPARδ) expression by HUVECs exposed to Hcy with or without telmisartan pretreatment was analyzed by RT-PCR and western blotting[]

  • Bezafibrate

    Author information 1 Department of Nutrition and Food, Harbin Medical University, Heilongjiang, China. [email protected] Abstract Fibrates, the ligands of peroxisome proliferator-activated[] However, bezafibrate has a unique characteristic profile of action since it activates all three PPAR subtypes (alpha, gamma and delta) at comparable doses.[] Receptors PPAR alpha RNA, Messenger Receptors, IgG Bezafibrate[] The goal of this study was to evaluate the effect of the peroxisome proliferator-activated receptor ligand bezafibrate on the progression of impaired fasting glucose phase[]

  • Pioglitazone

    Abstract Pioglitazone (PGZ), a peroxisome proliferator-activated receptor γ agonist, which is known as a type 2 diabetes drug, inhibits cell proliferation in various cancer[] Thus, pioglitazone can increase catalase activity by changing the BLC structure. Copyright 2017 John Wiley & Sons, Ltd.[] Abstract The peroxisome proliferator-activated receptor gamma (PPAR γ) agonists have been reported to have antiproliferative and tumor-suppressive effects.[] We used 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in a human model of lung inflammation to assess whether pioglitazone, a peroxisome proliferator-activated[]

  • Rosiglitazone

    Abstract Anti-inflammatory effects of peroxisome proliferator-activated receptor gamma (PPRAγ) ligands are thought to be largely due to PPARγ-mediated transrepression.[] Peroxisome proliferator-activated receptor gamma (PPARγ) is a member of the large nuclear hormone receptor transcription factor superfamily, and has been recently implicated[] Rosiglitazone (RSG), a thiazolidinedione ligand of the peroxisome proliferatoractivated receptor (PPAR) γ, has been found to inhibit proliferation, induce apoptosis, suppress[] Peroxisome proliferator-activated receptor (PPAR)γ activation, through rosiglitazone treatment, reduced the rate of α-GalCer-induced late PTB and improved neonatal survival[]

  • Clofibrate

    Clofibrate treatment reduced the proliferation of breast cancer cells probably by inhibiting NF-κB and ERK1/2 activation, reducing cyclinD1, cyclinA, cyclinE, and inducing[] Liver biopsies were taken after 2, 4, and 7 yr, to follow the peroxisomal response.[] Abstract The NADP -dependent dehydrogenase activity of a predominant isoenzyme of human liver 3alpha-hydroxysteroid dehydrogenase was activated by antihyperlipidemic drugs[] This increased binding was due to an increased affinity without a change in the number of insulin receptors.[]

  • Familial Partial Lipodystrophy

    We studied peroxisome proliferator-activated receptor-gamma (PPARgamma) gene as a candidate gene in seven FPL patients who did not appear to have Dunnigan variety.[] […] partial lipodystrophy (Dunnigan) type 3 (FPLD3, Mendelian Inheritance in Man [MIM] 604367) results from heterozygous mutations in PPARG encoding peroxisomal proliferator-activated[] The gene encoding retinoic acid receptor B (RARB) showed a higher methylation in all six patients with FPLD2 when compared with the progeria patients with other LMNA mutations[] activator receptor -γ (PPARG) mutation with those of a cluster of patients with familial partial lipodystrophy with classic codon 482 Lamin A/C (LMNA) mutations.[]

  • Peroxisomal Disease

    Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-α ligands, glucocorticoids, and insulin .[] Mutations in the PTS1 receptor gene, PXR1 receptor gene, PXR1, define complementation group 2 of the peroxisome biogenesis disorders.[] […] plasmalogens) glyceryl ether lipid levels were measured in post-mortem brain and/or liver biopsies from 7 patients with ultrastructural and biochemical evidence of a defect in peroxisomal[] We have restored SIRT1 activity using a dual strategy of resveratrol treatment or by the moderate transgenic overexpression of SIRT1 in a X-ALD mouse model.[]

  • Osteoporosis

    Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone . Diabetes 2000 ; 49: 539 – 47 .[] Moreover, compounds 3 , 6 - 9 , and 11 significantly suppressed TRAP activities.[] Overexpression of microRNA‑148a significantly reduced estrogen receptor a (ERα) protein expression and suppressed phosphoinositide‑3‑kinase regulatory subunit 1 (PI3K) and[] BACKGROUND: As for the association between vitamin D receptor (VDR) gene polymorphisms and osteoporosis, the current results have yielded conflicts.[]

  • Urokinase

    D2A peptide is as effective as EGF in promoting EGFR phosphorylation and cell proliferation that were inhibited by AG1478, a specific inhibitor of the tyrosine kinase activity[] receptors, and uPAR 88-92 is the minimal sequence required to induce cell motility through the Formyl Peptide Receptor type 1 (FPR1).[] […] protein level i Names & Taxonomy i Organism-specific databases Subcellular location i Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome[] Urokinase plasminogen activator (uPA) and its inhibitor plasminogen activator inhibitor-1 (PAI-1) are established independent biomarkers for high metastasis risk in breast[]